Key result
A P2Y12-specific assay revealed impaired clopidogrel responsiveness in 69% of treated CAD patients, with conventional aggregometry failing to detect 36% of these cases.
Why the study?
Does a P2Y12-specific assay (PRI) detect impaired clopidogrel responsiveness more frequently than conventional ADP-induced platelet aggregation in patients with CAD?
Cross-Sectional (n=133)
Does a P2Y12-specific assay (PRI) detect impaired clopidogrel responsiveness more frequently than conventional ADP-induced platelet aggregation in patients with CAD?
A P2Y12-specific assay (PRI) detects significantly more patients with impaired clopidogrel response than conventional ADP-induced platelet aggregation, revealing a 69% incidence of insufficient inhibition in a real-world CAD cohort.
Answers are grounded in this paper and cite their sources.
May warrant caution in relying on conventional aggregometry for clopidogrel response in CAD; leaves open need for outcome trials with P2Y12-specific assays.
Incomplete P2Y(12)-inhibition during clopidogrel treatment is associated with increased cardiovascular events and mortality after coronary intervention. We investigated the incidence of impaired individual clopidogrel-responsiveness using a P2Y(12)-specific and pre-treatment-independent assay in a real world situation. One hundred consecutive patients with coronary artery disease (CAD) on combined acetylsalicylic acid and clopidogrel treatment (75 mg/d) and 33 patients on aspirin only were screened for platelet ADP-induced signalling by conventional aggregometry, platelet P-selectin expression and the platelet reactivity index (PRI). Impaired P2Y(12)-specific inhibition by clopidogrel was defined as a PRI>50%. Functional platelet reactivity was significantly lower in clopidogrel-treated patients compared to controls. Impaired individual response to treatment was diagnosed in 69% of clopidogrel-treated patients. Conventional assessment of maximum ADP-induced platelet aggregation failed to detect impaired P2Y(12) inhibition in 36% of patients identified by PRI to have an impaired clopidogrel response. Impaired clopidogrel response was associated with lower HDL levels and a history of hyperlipidaemia. In conclusion, PRI as a P2Y(12)-specific assay to evaluate the treatment effect of clopidogrel in patients with CAD revealed insufficient P2Y(12)-inhibition in two thirds of patients in a real-world scenario indicating a markedly higher incidence than previously assumed. PRI detected significantly more patients with impaired response than conventional platelet aggregation.
No takes yet. Share an insight, caveat, or question.
Weinberger et al. (2008) conducted a cross-sectional in Coronary artery disease (n=133). Clopidogrel vs. Aspirin only was evaluated on Impaired individual response to clopidogrel treatment (PRI > 50%). A P2Y12-specific assay revealed impaired clopidogrel responsiveness in 69% of treated CAD patients, with conventional aggregometry failing to detect 36% of these cases.
Synapse has enriched 10 related papers. Consider them for comparative context: